Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171918 | 1.00 | KDM4E (0.44) | KDM4EMAP3K5HPGDTAS1R3TAS1R1 | |
| SCHEMBL12411796 | 0.83 | KDM4E (0.50) | KDM4EMAP3K5HPGDPIM1GRM4 | |
| SCHEMBL27814909 | 0.76 | KDM4E (0.50) | KDM4EMAP3K5HPGDPIM1GRM4 | |
| SCHEMBL16350201 | 0.74 | KDM4E (0.56) | KDM4E | |
| SCHEMBL3332997 | 0.73 | — | — | |
| SCHEMBL2407595 | 0.73 | HDAC1 (0.43) | — | |
| SCHEMBL15997875 | 0.73 | KDM4E (0.44) | KDM4EMAP3K5PIM1GRM4 | |
| Hydrochloric Acid SCHEMBL29462195 | 0.72 | KDM4E (0.53) | KDM4EMAP3K5HPGDPIM1GRM4 | |
| SCHEMBL28272930 | 0.71 | — | — | |
| SCHEMBL28191544 | 0.70 | KDM4E (0.52) | KDM4EMAP3K5PIM1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | KDM4E 422/4885MAP3K5 46/4885HPGD 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.